BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 26951627)

  • 1. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Yoon JH; Yhim HY; Kwak JY; Ahn JS; Yang DH; Lee JJ; Kim SJ; Kim JS; Park SJ; Choi CW; Eom HS; Park SK; Choi SY; Kim SH; Kim DW; Lee S
    Ann Oncol; 2016 Jun; 27(6):1081-1088. PubMed ID: 26951627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
    Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia.
    Yoon JH; Min GJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
    Cancer; 2019 Mar; 125(6):873-883. PubMed ID: 30521062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
    Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
    Czyz A; Lewandowski K; Kroll R; Komarnicki M
    Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Hara R; Onizuka M; Kikkawa E; Shiraiwa S; Harada K; Aoyama Y; Ogiya D; Toyosaki M; Suzuki R; Machida S; Ohmachi K; Ogawa Y; Kawada H; Matsushita H; Ando K
    Ann Hematol; 2021 Oct; 100(10):2479-2486. PubMed ID: 34247299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim DW; Cho BS; Yoon JH; Shin SH; Yahng SA; Lee SE; Eom KS; Kim YJ; Chung NG; Kim HJ; Min CK; Lee JW; Min WS; Park CW
    Leukemia; 2012 Nov; 26(11):2367-74. PubMed ID: 22705993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial.
    Dombret H; Gabert J; Boiron JM; Rigal-Huguet F; Blaise D; Thomas X; Delannoy A; Buzyn A; Bilhou-Nabera C; Cayuela JM; Fenaux P; Bourhis JH; Fegueux N; Charrin C; Boucheix C; Lhéritier V; Espérou H; MacIntyre E; Vernant JP; Fière D;
    Blood; 2002 Oct; 100(7):2357-66. PubMed ID: 12239143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of patients with development of large granular lymphocyte expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation.
    Ito Y; Miyamoto T; Kamimura T; Aoki K; Henzan H; Aoki T; Shiratsuchi M; Kato K; Nagafuji K; Ogawa R; Eto T; Iwasaki H; Akashi K
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e47-54. PubMed ID: 25445469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.
    Espérou H; Boiron JM; Cayuela JM; Blanchet O; Kuentz M; Jouet JP; Milpied N; Cahn JY; Faucher C; Bourhis JH; Michallet M; Tanguy ML; Vernant JP; Gabert J; Bordigoni P; Ifrah N; Baruchel A; Dombret H;
    Bone Marrow Transplant; 2003 May; 31(10):909-18. PubMed ID: 12748668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
    Hatta Y; Mizuta S; Matsuo K; Ohtake S; Iwanaga M; Sugiura I; Doki N; Kanamori H; Ueda Y; Yoshida C; Dobashi N; Maeda T; Yujiri T; Monma F; Ito Y; Hayakawa F; Takeuchi J; Kiyoi H; Miyazaki Y; Naoe T
    Ann Hematol; 2018 Sep; 97(9):1535-1545. PubMed ID: 29694642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.
    Lussana F; Intermesoli T; Gianni F; Boschini C; Masciulli A; Spinelli O; Oldani E; Tosi M; Grassi A; Parolini M; Audisio E; Cattaneo C; Raimondi R; Angelucci E; Cavattoni IM; Scattolin AM; Cortelezzi A; Mannelli F; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Romani C; Bassan R; Rambaldi A
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1983-1987. PubMed ID: 27492792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG).
    Wrzesień-Kuś A; Robak T; Pluta A; Zwolińska M; Wawrzyniak E; Wierzbowska A; Skotnicki A; Jakubas B; Hołowiecki J; Nowak K; Kuliczkowski K; Mazur G; Haus O; Dmoszyńska A; Adamczyk-Cioch M; Jedrzejczak WW; Paluszewska M; Konopka L; Pałynyczko G
    Ann Hematol; 2006 Jun; 85(6):366-73. PubMed ID: 16523310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
    Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
    Ravandi F; Jorgensen JL; Thomas DA; O'Brien S; Garris R; Faderl S; Huang X; Wen S; Burger JA; Ferrajoli A; Kebriaei P; Champlin RE; Estrov Z; Challagundla P; Wang SA; Luthra R; Cortes JE; Kantarjian HM
    Blood; 2013 Aug; 122(7):1214-21. PubMed ID: 23836561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia.
    Chang J; Douer D; Aldoss I; Vahdani G; Jeong AR; Ghaznavi Z; Zhang S; Yaghmour G; Lee KJ; Weissman A; Akhtari M
    Cancer Med; 2019 Jun; 8(6):2832-2839. PubMed ID: 31016870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
    Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
    Benjamini O; Dumlao TL; Kantarjian H; O'Brien S; Garcia-Manero G; Faderl S; Jorgensen J; Luthra R; Garris R; Thomas D; Kebriaei P; Champlin R; Jabbour E; Burger J; Cortes J; Ravandi F
    Am J Hematol; 2014 Mar; 89(3):282-7. PubMed ID: 24779033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Wang J; Jiang Q; Xu LP; Zhang XH; Chen H; Qin YZ; Ruan GR; Jiang H; Jia JS; Zhao T; Liu KY; Jiang B; Huang XJ
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):741-750. PubMed ID: 29247779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.